AN2 Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -10,003 | -9,353 | -7,216 | -11,537 |
EBIT | -7,216 | -11,537 | ||
Net Income | -8,710 | -9,353 | -6,462 | -10,649 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -5,236 | -6,375 | -7,599 | -10,624 |
Cash | 19,941 | 18,003 | 18,220 | 19,985 |
Basic Shares | 30,215 | 30,276 | 30,172 | 30,054 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -77 | |||
EBITDA | -38,109 | 3,233 | 4,903 | -43,468 |
EBIT | -51,321 | -64,732 | -42,262 | |
Net Income | -35,174 | -51,321 | -64,732 | -41,470 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -29,834 | -49,257 | -53,288 | -33,462 |
Cash | 19,941 | 21,351 | 15,647 | 27,219 |
Basic Shares | 30,215 | 29,828 | 23,600 | 15,340 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.29 |
2025-09-30 | -$0.31 |
2025-06-30 | -$0.21 |